U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07552168) titled 'INSPIRE: INnovative SABR for Prostate Cancer All IREland' on April 07.
Brief Summary: This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer. Eligible patients will receive next generation prostate SABR incorporating toxicity reduction strategies
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Prostate Adenocarcinoma
Intervention:
RADIATION: Next generation Stereotactic Ablative Radiotherapy (SABR)
Treatment will prioritise the dominant intraprostatic lesion ...